FPF 1070

Drug Profile

FPF 1070

Alternative Names: Cerebrolysin

Latest Information Update: 20 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ebewe Neuro Pharma
  • Developer EVER Neuro Pharma
  • Class Nootropics; Peptides; Tissue extracts
  • Mechanism of Action Neuron stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Stroke
  • Discontinued Brain injuries

Most Recent Events

  • 10 Nov 2016 Launched for Stroke in Poland (IV)
  • 29 Dec 2010 EVER Neuro Pharma completes a phase-II trial in Stroke in Poland (EudraCT2007-000870-21)
  • 18 Aug 2009 Discontinued - Phase-II for Brain injuries in Austria (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top